webex: https://uwhealth.webex.com/uwhealth/j.php?MTID=m3e0079841c164c924e50bf2b3a66aaaf

Objectives:

1. Describe the pathophysiology, etiology, and current medications available for the treatment of lupus nephritis
2. Discuss the mechanism of action, indications for use, monitoring, and adverse reactions associated with obinutuzumab
3. Summarize the results of a recent randomized, double blind, placebo-controlled trial regarding the use of obinutuzumab for the treatment of class III or IV lupus nephritis
4. Describe the mechanism of action of GLP-1 receptor agonists and effect on gastric emptying time
5. Identify potential concerns for perioperative use and define current recommendations
6. Discuss organ-specific considerations and future directions
7. Identify the need for expanding the solid organ donor pool and how that can be achieved by including hepatitis B and C positive donors
8. Describe the pharmacologic therapies currently utilized in solid organ transplantation from a hepatitis C positive donor
9. Explain the considerations for using a hepatitis B positive donor in solid organ transplantation and possible pharmacologic interventions